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BACKGROUND: Whether there are lifetime points of greater sensitivity to the deleterious effects of alcohol intake on the breasts
remains inconclusive.
OBJECTIVE: To compare the influence of distinctive trajectories of alcohol consumption throughout a woman’s life on
development of breast cancer (BC).
METHODS: 1278 confirmed invasive BC cases and matched (by age and residence) controls from the Epi-GEICAM study (Spain)
were used. The novel group-based trajectory modelling was used to identify different alcohol consumption trajectories throughout
women’s lifetime.
RESULTS: Four alcohol trajectories were identified. The first comprised women (45%) with low alcohol consumption (<5 g/day)
throughout their life. The second included those (33%) who gradually moved from a low alcohol consumption in adolescence to a
moderate in adulthood (5 to <15 g/day), never having a high consumption; and oppositely, women in the third trajectory (16%)
moved from moderate consumption in adolescence, to a lower consumption in adulthood. Women in the fourth (6%) moved from
a moderate alcohol consumption in adolescence to the highest consumption in adulthood (≥15 g/day), never having a low alcohol
consumption. Comparing with the first trajectory, the fourth doubled BC risk (OR 2.19; 95% CI 1.27, 3.77), followed by the third (OR
1.44; 0.96, 2.16) and ultimately by the second trajectory (OR 1.17; 0.86, 1.58). The magnitude of BC risk was greater in
postmenopausal women, especially in those with underweight or normal weight. When alcohol consumption was independently
examined at each life stage, ≥15 g/day of alcohol consumption in adolescence was strongly associated with BC risk followed by
consumption in adulthood.
CONCLUSIONS: The greater the alcohol consumption accumulated throughout life, the greater the risk of BC, especially in
postmenopausal women. Alcohol consumption during adolescence may particularly influence BC risk.
British Journal of Cancer (2021) 125:1168–1176; https://doi.org/10.1038/s41416-021-01492-w
INTRODUCTION
Breast cancer (BC) remains the most frequently diagnosed cancer
in women in the majority of the countries worldwide, abruptly
disrupting the lives of millions of women [1]. Amongst the
aetiological factors proposed to be implicated in developing BC,
reproductive history has been one of the most consistent [2].
Likewise, alcohol consumption is the only significant and
consistently clinically supported single dietary risk factor for BC
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[3–5]. Although a linear association between alcohol consumption
and BC is firmly established [5], whether alcohol consumption acts
early in the process of breast tumorigenesis and whether there are
time points in the lifespan of greater sensitivity to the deleterious
effects of ethanol on women’s breasts remain unanswered.
Compared with other organs, the breast appears to be more
susceptible to the carcinogenic effects of alcohol, particularly from
menarche to the first pregnancy, since the mammary glands are
not completely differentiated [6–8]. Human data supports that
exposures before the first pregnancy may be more critical in BC
development than exposures later in life [8–11].
Nonetheless, previous epidemiological studies on BC addres-
sing alcohol consumption at different periods throughout life
have generated inconsistent results, and the risk attributable to
alcohol consumed during young ages remains uncertain [12].
To improve upon past research and to afford a most comprehen-
sive evaluation of the effect of alcohol consumption throughout a
woman’s life, we aimed to chart out different life trajectories of
alcohol consumption using a novel methodology, the Group-
Based Trajectory Modeling (GBTM), and compare them in terms of
the risk of BC, overall, by menopausal status and by pathologic
subtype. This novel statistical method identifies clusters of women
who followed similar patterns of alcohol consumption over time.
This approach has the advantage over traditional analysis of
capturing the life course alcohol consumption [13, 14] rather than
cumulative consumption over time or single consumptions at
different time periods (without considering the impact of alcohol
consumption during any other period). To our knowledge, this the
first study to evaluate trajectories of alcohol consumption over the
life in relation to BC risk.
METHODS
Study design and population
Present data come from the EpiGEICAM study, a multicenter 1:1 matched
case–control study on female BC. To be eligible for the study, participants
had to reside in one of the hospitals´ catchment area, be between 18–70
years old and be able to complete the epidemiological questionnaire. The
global participation rate was 82% (75% in cases and 90% in controls).
Thus, 1017 women newly diagnosed with BC, and histologically
confirmed, were recruited, between 2006 and 2011, in the Oncology
Departments of 23 hospitals which are members of the Spanish Breast
Cancer Research Group, GEICAM (http://www.geicam.org/). These hospitals
are situated in 9 Spanish Autonomous Regions, accounting for 78% of the
Spanish population. Each BC case was matched with a healthy control
residing in the same town and of similar age (±5 years), generally selected
by the case (non-blood relatives, friends, neighbours, work colleagues).
Patients´ blood-relatives were not eligible. Cases were subclassified based
on tumour characteristics according to expression of oestrogen receptor
(ER), progesterone receptor (PR), and luminal human epidermal growth
factor receptor 2 (HER2):(i) HER2 negative tumours (ER+ or PR+ with
HER2–); (ii) HER2 positive tumours (HER2+ irrespective of ER or PR status);
and (iii) triple-negative tumours (ER–, PR– and HER2–) [15–17].
Data collection
Cases and controls filled a structured questionnaire which recorded
demographic and anthropometric data, personal and family background,
medical and occupational history and lifestyle and dietary information.
Cases completed the questionnaire within 3 months after diagnosis of BC.
When questions referred to a specific time period for cases, the
corresponding control was asked about the same calendar period.
Data collected for each participant included age, educational level,
height and weight, personal medical history (with special emphasis on
obstetric and gynaecological background) including menopausal status,
age at menarche, number of children, age at first birth, use of hormone
replacement therapy (HRT), and previous diagnosis of benign breast
diseases; occupational history, family history of BC, physical activity during
the previous year, smoking status, and diet. Based on the highest
educational level achieved, participants were classified into 3 categories:
primary school or less, secondary school, and university graduate or higher.
Body mass index (BMI) was calculated based on participant’s self-reported
weight one year before the interview and height. Postmenopausal status
was defined as the absence of menstruation in the last 12 months. Physical
activity during the previous year was collected through a detailed
questionnaire and recreational, occupational, and household activities
were considered to classifying women using 3 categories: sedentary/
lightly active, moderately and active/very active [18, 19].
Dietary intake in the past 5 years was measured using a 117-item
semiquantitative food frequency questionnaire (FFQ), similar to the
Harvard questionnaire [20], adapted to and validated in different Spanish
adult populations [21, 22]. Total intake of each nutrient and of total energy
was computed for each participant. Adherence to a Mediterranean dietary
pattern, previously identified from the control group, was calculated [23].
The questionnaire was self-fulfilled and then jointly reviewed by the
participant and a trained interviewer in each centre. Data entry and quality
control were performed at the GEICAM headquarters. The accuracy of the
information registered in the database was verified randomly selecting and
reviewing 10% of the questionnaires.
Alcohol consumption assessment
The FFQ had a specific module for the detailed measurement of
the consumption of different alcoholic beverages. Participants had nine
options to describe how frequently they consumed each type of beverage
–ranging from ‘never or less than once per month’ to ‘six or more times
per day’—at specific life stages —adolescence (12–19 years), young
adulthood (20–29 years) and adulthood (in the recent 5-year period). The
different drinks included were wine (red, white, rosé), vermouth-type
alcohols (sherry, dry wines), beer, cider, cava and high-grade distillated
spirits (40°, such as brandy, gin, rum, whiskey, vodka and tequila).
Responses were converted to mean daily grams (g) of alcohol consumed
by multiplying consumption frequency by the corresponding typical
ethanol content (g) of each alcoholic beverage [24] and its standard
serving sizes specified in the FFQ (e.g. the serving size of red wine is 125 cc,
while the serving size of beer is 200 cc and for liquor it is 50 cc). Finally,
consumption of each type of alcoholic beverage and consumption of total
alcohol (g/day) were computed for each participant and for each of the
three life stages. Total alcohol consumption was categorised in low,
moderate and high according to previous published cut off points: <5, 5–
<15 and ≥15 g/day [25, 26].
Statistical methods
In the group-based trajectory modelling (GBTM), a group is conceptually
thought of as a latent longitudinal stratum where population variability is
captured by differences across groups in the shape and level of their
trajectories. This method fits longitudinal data as a discrete mixture of two
or more trajectories via maximum likelihood [27]. In this study, the GBTM
was used to identify different alcohol consumption trajectories throughout
the life of those women with alcohol consumption data (categorised into
low, moderate and high according to the cut off points: <5, 5–<15 and
≥15 g/day) in each of the life stages: adolescence (12–19 yr.), young
adulthood (20–29 yr.) and adulthood (≥30 yr.).
To fit the models, we used the Stata traj plug-in, and total alcohol
consumption (g/day) modelled as a censored normal distribution and as a
polynomial function of age (as time scale). The model selection was carried
out using an approach that consisted of two-stages assessing the change
in the Bayesian Information Criterion (BIC) [28]. In the first stage, we
determined the number of groups using a quadratic form for all the
trajectory groups, and selected the model with the best BIC [28]. Once we
identified that the model with four groups fit best, in the second stage, we
aimed to determine the order of the polynomial functions (1 or 2)
specifying the shape of each trajectory. The BIC indicated that the best
model included the quadratic order term. This process was followed using
the entire sample, as well as separately for cases and controls, consistently
obtaining the same trajectory groups. The average posterior probability
(APP) of an individual’s belonging to each of the trajectory groups was
tested to verify the model´s adequacy. The APP of group membership
measured the likelihood of each participant belonging to its assigned
group. We used an APP ≥ 0.70 as the cutoff point [28]. Finally, to assess the
assignment accuracy, we calculated the odds of correct classification (OCC)
and consider that an OCC greater than 5.0 indicated that the model had a
high assignment accuracy [28] (Table S1). These trajectories should be
interpreted as groups of women following similar patterns of alcohol
consumption across their life-course [29].
Participants’ characteristics were compared between cases and controls
and across the four alcohol consumption trajectories, using counts and
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percentages for categorical variables and means and standard deviations
for continuous variables. To check the statistical significance of
case–control differences we used Pearson Chi-square test (for categorical
variables), Student’s t-test (for continuous variables), and for variables with
imputed values, p values resulting from logistic regression models.
To evaluate the association between life course alcohol consumption
and BC, we first explored independently for each of the three life stages
(adolescence, young adulthood, and adulthood), the association between
total alcohol consumption (low, moderate, high) and the risk of BC. Next, as
the main analysis, we assessed the association of the trajectories of alcohol
identified by the GBTM with BC risk. For these analyses we fitted
conditional logistic regression models, estimating odds ratios (ORs) and
their 95% confidence intervals (CI)
Additionally, we performed analyses stratified by menopausal status
and, among postmenopausal women, also by BMI (<25 and ≥25 kg/m2).
For these analyses, we used unconditional logistic regression models. We
further assessed the modifier effect by menopausal status and BMI by
testing the interactions (likelihood-ratio test) between these variables and
the trajectories of alcohol consumption.
To test whether the associations varied across pathological BC subtypes,
we used multinomial logistic regression models with pathological subtype
as the dependent variable and the control group as the reference (base
outcome). OR (also referred to as relative risk ratios (RRRs) and their 95% CI
were estimated and the heterogeneity of effects for the different BC
subtypes was tested using the Wald statistic.
Among factors that could potentially confound the association between
alcohol and BC, we included those covariates that changed the estimates
by more than 5% in the main assessment. Thus, in addition to age and
residence (matching variables), in the multivariate models we included
body mass index (BMI) one year before entry in the study (<25, 25–<30,
≥30 kg/m2) and menopausal status (these two included with their
corresponding interaction terms), educational level (primary school or
less, secondary school, university graduate or higher), smoking status
(never smoker, ex-smoker for ≥6 months and smoker or ex-smoker for
<6 months), physical activity (sedentary/lightly active, moderately active,
active/very active), total calories intake (continuous), level of adherence to
the Mediterranean dietary pattern (quartiles based on controls), age at
menarche (years), age at the first birth (years with a category of
nulliparous), number of children (continuous), chronic diseases (yes/no),
previous benign breast diseases (yes/no), family history of BC (yes/no), and
hormone replacement therapy (HRT) use (yes/no).
Some variables contained missing values: BMI (9%), educational level
(<1%), smoking (<0.5%), physical activity (7%), calories intake (3%),
adherence to the Mediterranean dietary pattern (3%), age at menarche
(0.6%), age at first birth (4%), previous benign breast lesions (2%), and HRT
use (5%). In order to obtain unbiased estimates of the effect of each
alcohol consumption trajectory using the information provided by all
case–control pairs, missing values were imputed using multiple imputa-
tions with chained equations with 7 predictors (age, educational level,
number of children, menopausal status, previous benign breast diseases,
family history of BC and case/control status) and 5 imputations [30, 31].
The validity of the imputation was checked by comparing the results
obtained with those resulting from the analyses of the data with complete
information.
All p values presented are two-tailed; <0.05 was considered statistically
significant. Analyses were carried out using STATA/SE version 16.0
(StataCorp, College Station, TX, USA).
RESULTS
Out of the 2034 recruited women (1017 case–control pairs), 1578
(799 controls and 779 cases) had complete longitudinal data on
alcohol consumption (i.e. alcohol data in all three life stages).
Among these women, 925 were premenopausal and 653
postmenopausal. 70.3% (n= 546) of the cases had a luminal
tumour (ER+ and/or PR+ with HER2 negative), 18.5% (n= 144)
had a HER2+ tumour and the remaining 11.2% (n= 87) had a TN
(ER−, PR− and HER2) tumour (Table S2).
The average age was 49 (±9) years old for both cases and
controls. On average, compared with controls, cases had a
statistically significant lower educational level, lower proportion
of postmenopausal women, had more frequently family history of
breast cancer (first or second degree), a lower frequency of
chronic diseases and slightly higher caloric intake (Table 1).
Overall, no other meaningful differences in baseline characteristics
were observed between cases and controls. Regarding alcohol
consumption, on average, cases consumed more alcohol in all life
stages, adolescence, young adulthood, and adulthood, compared
with controls (p value < 0.05).
When exploring the association between categories of alcohol
consumption and the risk of BC in each of the life stages (Table 2),
consumption during adolescence and adulthood were indepen-
dently related to BC risk. Compared to those with less alcohol
consumption (<5 g/day), women consuming ≥15 g/day in adoles-
cence (OR 2.46; 95% CI 1.04, 5.86; P for trend 0.038) and in
adulthood (in the last 5 years) (OR 1.93; 95% CI 1.13, 3.29; P for
trend 0.029) had about twice the risk of BC, regardless of
consumption during the other two corresponding life stages.
However, consumption during young adulthood was not asso-
ciated with a major BC risk when adjusting for alcohol
consumption during adolescence and adulthood (OR 0.87; 95%
CI 0.48, 1.58; P for trend 0.932) (Table 2).
The best model identified by the GBTM involved four
trajectories of alcohol consumption over the women´s lifetime
(Fig. 1, Table S1), consistently when using the entire sample, as
well as, when only using controls (Fig. S1). The first trajectory
(followed by 45% of participants) comprised women who had
consumed less than 5 g/d of alcohol throughout life. The second
trajectory (33%) included those who progressively moved
from a low alcohol consumption in adolescence (<5 g/day) to
a moderate consumption in adulthood (5 to <15 g/day), never
having a high consumption. Women in the third trajectory (16%)
kept a moderate consumption throughout their lives. Finally,
women in the fourth trajectory (6%) moved from a moderate
alcohol consumption in adolescence (5 to <15 g/day) to a higher
consumption in young adulthood (≥15 g/day).
When comparing the characteristics of control women follow-
ing the four alcohol trajectories shown in Table S3, apart from
alcohol intake, there were differences in age, tobacco consump-
tion, age at first birth and history of benign breast lesions. Women
in the fourth trajectory were more frequently smokers, had their
first child at a later age and reported more frequently a history of
benign breast lesion.
Table 3 shows the association between these lifetime trajec-
tories of alcohol consumption and BC risk in the total sample and
by menopausal status and BMI. Overall, a growing positive
association between sequential trajectories and BC was observed.
That is, comparing with the first trajectory, the fourth trajectory
was the most strongly associated with BC (OR 2.19; 95% CI 1.27,
3.77), followed by the third trajectory (OR 1.44; 95% CI 0.96, 2.16)
and ultimately by the second one (OR 1.17; 95% CI 0.86, 1.58).
Thus, women with moderate consumption in adolescence that
increased to a higher consumption in adulthood (fourth trajectory)
had twice the risk of BC compared with women consuming less
than 5 g/day of alcohol throughout life (first trajectory). When we
analysed by menopausal status, although the trend of the
associations remained, their magnitude with respect to the global
ones, became greater in the group of postmenopausal women
and diminished in premenopausal women.
In postmenopausal women, trajectories were associated with
BC with fully adjusted ORs of 2.33 (95% CI 1.11, 4.93), 1.79 (95% CI
1.02, 3.15) and 1.22 (95% CI 0.83, 1.79), respectively, for the fourth,
third and second trajectories compared with the first one. In
premenopausal women, although none of the trajectories reached
statistical significance, the trajectories showed similar magnitudes
of effect estimates. When postmenopausal women were sepa-
rately analysed according to BMI, the magnitude of the effect
estimates were significantly greater in slender postmenopausal
women, even though the same trend was observed in both BMI
groups. Postmenopausal women with a BMI < 25 in the fourth
alcohol trajectory had about three times higher BC risk (95% CI
C. Donat-Vargas et al.
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1.14, 9.39) compared with those in the first trajectory. However,
the test for interaction between alcohol and BMI, as well as alcohol
and menopausal status were not statistically significant (P value
from likelihood-ratio test >0.1).
Finally, when examining the association between alcohol
trajectories and BC risk by pathological subtype, no significant
differences (Wald test p value >0.05) were seen, except for the
luminal HER2 negative subtype (ER+/PR+ and HER2−) (OR,
alcohol trajectory 4 vs 1, 1.73; 95% CI 1.07, 2,82). Estimations for
the other two subtypes failed to attain statistical significance
probably due to the limited number of cases (Tables S2 and S4).
DISCUSSION
In this case–control study of 1578 pre-and postmenopausal
women, some main observations about the alcohol trajectories
identified should be emphasised: (1) half of the participants
reported no or very mild consumption of alcohol throughout life
(2) those women who already drank during adolescence and
young adulthood, continued to drink similarly or more during
adulthood and, (3) when examined separately, ≥15 g/day of
alcohol consumption at adolescence and in adulthood (in the last
5 years) were both strongly and independently associated with BC
risk. Likewise, a growing positive association between sequential
trajectories and BC risk was consistently observed, particularly in
postmenopausal and for the luminal HER2 negative subtype (70%
of the cases).
Taking none or very low alcohol consumption throughout life as
reference, the fourth trajectory (those who moved from a
moderate alcohol consumption in adolescence to a higher
consumption in adulthood, never having had a low alcohol
consumption) was always the most strongly associated with BC,
followed by the third trajectory (those who kept a moderate
consumption throughout their lives) and ultimately by the second
trajectory (those who gradually moved from a low alcohol
consumption to a moderate consumption in adulthood, never
having a high consumption). These results suggest that the
greater the alcohol consumption accumulated throughout life, the
greater the risk of BC; but also, that alcohol consumption during
adolescence may particularly influence BC risk. In fact, the BC risk
corresponding to the third trajectory was greater than that for the
second trajectory; and whereas this trajectory 2 increases from a
low alcohol consumption in adolescence to a moderate con-
sumption in young and late adulthood, the trajectory 3 starts with
Table 1. Distribution of baseline characteristics for cases and controls: the EpiGEICAM study.
Characteristics Total (N= 1578) Controls (N= 799) Cases (N= 779) P valuea
Alcohol consumption, g/day, mean (±SD)
Adolescence 2.8 ± 5.7 2.4 (±4.0) 3.3 (±7.0) <0.01
Young adulthood 5.4 ± 8.4 4.8 (±6.6) 6.1 (±9.9) <0.01
Adulthood 6.8 ± 10.0 6.0 ± (8.3) 7.6 (±11.4) <0.01
Age, years, mean (±SD) 49 ± 9 49 (±9) 49 (±9) 0.87
Body mass index, Kg/m2, mean (±SD) 25.2 ± 4.6 25.1 (±4.4) 25.3 (±4.7) 0.42
Postmenopausal, n (%) 653 (41.4) 352 (44.1) 301 (38.6) 0.03
Educational level, n (%) 0.05
Primary school or less 239 (15.2) 116 (14.5) 123 (15.8)
Secondary school 815 (51.7) 395 (49.4) 420 (53.9)
University graduate or higher 524 (33.2) 288 (36.1) 236 (30.3)
Smoking status, n (%) 0.35
Never smoker 568 (36.0) 281 (35.2) 287 (36.9)
Ex-Smoker (≥6 months) 465 (29.5) 233 (29.2) 231 (29.7)
Smoker (or ex-smoker <than 6 months) 545 (34.5) 285 (35.6) 260 (33.4)
Physical activity, n (%) 0.07
Sedentary/lightly active 541 (34.2) 247 (31.0) 292 (37.6)
Moderately active 598 (37.9) 326 (40.8) 273 (35.0)
Active/very active 439 (27.8) 226 (28.2) 214 (27.4)
Calories, kcal/day, mean (±SD) 1952 (±633) 1906 (±632) 2000 (±622) <0.01
Adherence to the Mediterranean dietary pattern, score 1–10, mean (±SD) 5.9 (±1.4) 6.0 (±1.4) 5.8 ± (1.3) 0.06
Age at menarche, years, mean (±SD) 12 (±1.5) 12 (±1.5) 12 (±1.5) 0.11
Age at first birth, years, mean (±SD) 26 (±5.0) 26 (±5.0) 27 (±5.0) 0.08
Number of children, mean (±SD) 1.6 (±1.2) 1.6 (±1.2) 1.5 (±1.1) 0.22
Chronic diseases, n (%) 635 (40.2) 341 (42.7) 294 (37.7) 0.05
Previous benign breast problems, n (%) 316 (20.0) 152 (19.0) 164 (21.1) 0.31
Family history of breast cancer, n (%) 358 (22.7) 153 (19.2) 205 (26.3) <0.01
Hormone replacement therapy use, n (%) 161 (10.2) 77 (9.6) 84 (10.8) 0.43
Data correspond to observed values for age, number of children, menopausal status, chronic diseases, family history of breast cancer and alcohol
consumption, and to imputed values for the remaining variables in the table.
Bold values indicate statistical significance p ≤ 0.05.
SD standard deviation
aP value resulting from Pearson Chi-Square test (categorical variables with no missing values), from Student’s t test (continuous variables with no missing
values), and from logistic regression models (variables with imputed values).
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a moderate consumption in adolescence, maintained during
young adulthood, and goes to a lower consumption in adulthood.
In view of this, alcohol consumption in early ages could acquire
more weight than consumptions later in life in relation to BC risk
later in life. Despite the caution required due to the 95% CIs overlap,
this interpretation is reinforced by the results presented in Table 2;
when alcohol consumption was independently examined at each
life stage, ≥15 g/day of alcohol consumption in adolescence which
was strongly associated with BC risk, followed by this consumption
during adulthood (in past 5-year period). These findings add support
to the importance of exposure between menarche and the first
pregnancy in breast cancer development [9] but also the
importance of considering the totality of a woman’s exposure to
alcohol over her lifetime as the best measure, rather than those from
one specific periods [32].
Some previous studies exploring whether intake during specific
periods influenced BC risk, also reported similar and independent
contributions of alcohol consumption during the early adult
years and later adult years to BC risk [32–36]. The strongest
methodologically was a prospective observational study of
105,986 women enrolled in the Nurses’ Health Study (NSH)
followed from 1980 until 2008 with early adults and eight updated
alcohol assessments during this period. An observed association
between even low levels of alcohol consumption and BC risk was
observed. While the most relevant measure was cumulative
average alcohol consumption over long periods both drinking
earlier (between the ages of 18–40) and later (after the age of 40)
in adult life were independently associated with BC risk [32]. In
other investigations, an increased BC risk was evident only for
those who consumed alcohol at young ages [37, 38], while others
found that early alcohol consumption was not an important
determinant of risk, or even that alcohol consumption later in life
was the greatest influence on BC risk [39–41].
It is worth noting that in these studies the timing of alcohol
consumption was evaluated using different chronological age
cut-offs and mixing exposure both before and after the first
pregnancy. These discrepancies may help explain the incon-
sistent results on the impact of alcohol consumption in early
adult life. Thus, in these studies, young ages and early
consumption have been defined as less than 30 yrs.
[35, 37, 41], between 15 and 20 yrs. [39], between 18 and 35
yrs. [36] or between 18 and 40 [32], to give but some examples.
However, when alcohol consumption before and after the first
pregnancy was explicitly addressed, alcohol consumption prior
to the first full-time pregnancy seems to be more consistently
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Fig. 1 GBTM was used to identify different alcohol consumption
trajectories throughout the life of those women with alcohol
consumption data (categorised into low, moderate, and high
according to the cut off points: <5, 5–<15 and ≥15 g/day; X axis) in
each of the life stages: adolescence (12–19 yr.), young adulthood
(20–29 yr.) and adulthood (≥30 yr.); Y axis. The percentages
assigned to each trajectory represent the percentage of women
out of the total sample (N= 1578) following that trajectory of
alcohol consumption.
Table 2. Association between alcohol consumption in each life stage and breast cancer occurrence, estimated from three models including different
sets of adjusting variables.
Total alcohol consumption (g/day) Co. Ca. Model 1a OR (95% CI) Model 2b OR (95% CI) Model 3c OR (95% CI)
Adolescence (n= 1314; 657 paired case–control)
<5 560 526 1 (ref.) 1 (ref.) 1 (ref.)
5–<15 82 103 1.36 (1.00. 1.87) 1.37 (0.96. 1.95) 1.31 (0.89. 1.94)
≥15 15 28 2.17 (1.11. 4.26) 2.63 (1.22. 5.64) 2.46 (1.04. 5.86)
P for trend 0.011 0.006 0.038
Young adulthood (n= 1410; 705 paired case–control)
<5 470 431 1 (ref.) 1 (ref.) 1 (ref.)
5–<15 184 200 1.22 (0.95. 1.56) 1.35 (1.02. 1.80) 1.13 (0.80. 1.59)
≥15 51 74 1.68 (1.12. 2.51) 1.66 (1.05. 2.60) 0.87 (0.48. 1.58)
P for trend 0.002 0.006 0.932
Adulthood (n= 1448; 724 paired case–control)
<5 431 414 1 (ref.) 1 (ref.) 1 (ref.)
5–<15 221 198 0.96 (0.75. 1.23) 1.03 (0.78. 1.35) 0.96 (0.70. 1.32)
≥15 72 112 1.80 (1.25. 2.60) 2.09 (1.37. 3.20) 1.93 (1.13. 3.29)
P for trend 0.002 0.004 0.030
To test for linear trends across increasing categories of alcohol consumption, the median concentration within each category was included and treated as a
continuous variable in the model.
Ca cases, Co controls, OR odds ratio, CI confidence interval.
aAdjusted for age at the time of recruitment and hospital.
bAdditionally adjusted for BMI, menopausal status, an interaction term between BMI and menopausal status, calories, age at menarche, number of children,
age at first child, smoking status, educational level, chronic diseases, hormone replacement therapy use, previous benign breast lesions, family history of
breast cancer, physical activity, adherence to the Mediterranean dietary pattern.
cAdditionally adjusted for alcohol consumption during the other stages of life (n= 1.278).
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A breast with undifferentiated structures has a high rate of
cell proliferation and is more predisposed to undergo malignant
transformation. Thus, the time period from menarche to the first
pregnancy is a window of time when breast tissue seems to
be particularly susceptible to carcinogens and neoplastic
transformation [7]. It has been observed in rat models that
the tumorigenic response is maximal when the carcinogen is
administered during critical adolescence period, in which the
mammary gland is undifferentiated and highly proliferating.
Administration of carcinogens to pregnant or parous rats, on
the other hand, fails to elicit a tumorigenic response, explained
by the complete development of the gland attained during
pregnancy [42].
The strong association between alcohol consumption in
adolescence and BC risk observed in our study might be
understood in the light of these data supporting the importance
of exposure between menarche and the first pregnancy in BC
development. On the other hand, the lack of association between
alcohol consumption in young adulthood (20–29 yrs.) and BC
could be explained because most women (~80%) gave birth
during this period of life (stage of life), thus being less vulnerable
to the carcinogenicity of alcohol than in the previous life stage(s)
[9]. Having information on alcohol consumption both before and
after giving birth would have been of interest in order to more
precisely define these risk periods.
Lifetime exposure to oestrogens appears to be one mechan-
ism underlying the association between alcohol and all types of
mammary cancers, hormone-dependent and hormone-
independent [43, 44]. Several studies have shown positive
correlations between alcohol intake and plasma or urinary
oestrogen levels [45–49]. This increased oestrogen level in
women consuming alcohol is hypothesised to be due either to a
decrease in the metabolic clearance of oestrogens or to
increased secretion [50, 51]. The apparent carcinogenicity of
oestrogens is attributed to receptor-mediated stimulation of
cellular proliferation, that could result in-turn in accumulation of
genetic damage and stimulation of the synthesis of growth
factors that act on the mammary epithelial cells [42, 52].
Alcohol may also affect BC risk by acting as a co-carcinogen,
improving the permeability of membranes to carcinogens,
inhibiting their detoxification, and activating procarcinogens
[53]. Alcohol also seems to influence the disposition and
function of essential nutrients or dietary factors considered to
be cancer protective, through the modification of folate status
or a decrease of concentrations of B-carotene, lutein/zeaxanthin,
and vitamin C [54].
In this study, the stronger effect observed in postmenopausal
women and particularly in those no overweight or obese
(although the interactions were not statistically significant), could
be partly explained by the oestrogenic effect of alcohol, that
Table 3. Association between alcohol consumption trajectories and breast cancer occurrence: total sample, by menopausal status and by body mass
index in postmenopausal women.
Alcohol consumption trajectories Controls Cases Model 1a OR (95% CI) Model 2b OR (95% CI)
Total (N= 1278; 639 paired Ca/Co)
Trajectory 1 304 280 1 (ref.) 1 (ref.)
Trajectory 2 228 216 1.05 (0.80. 1.37) 1.17 (0.86. 1.58)
Trajectory 3 70 86 1.38 (0.96. 1.97) 1.44 (0.96. 2.16)
Trajectory 4 37 57 1.79 (1.12. 2.88) 2.19 (1.27. 3.77)
Premenopausal (n= 925)
Trajectory 1 217 212 1 (ref.) 1 (ref.)
Trajectory 2 151 160 1.07 (0.80. 1.43) 1.11 (0.81. 1.52)
Trajectory 3 53 68 1.35 (0.89. 2.03) 1.36 (0.88. 2.10)
Trajectory 4 26 38 1.48 (0.86. 2.52) 1.46 (0.82. 2.59)
Postmenopausal (n= 653)
Trajectory 1 186 141 1 (ref.) 1 (ref.)
Trajectory 2 117 98 1.12 (0.79. 1.58) 1.22 (0.83. 1.79)
Trajectory 3 32 38 1.66 (0.98. 2.82) 1.79 (1.02. 3.15)
Trajectory 4 17 24 1.92 (0.99. 3.72) 2.33 (1.11. 4.93)
Body mass index < 25 kg/m2 (n= 263)c
Trajectory 1 74 49 1 (ref.) 1 (ref.)
Trajectory 2 51 39 1.14 (0.66. 1.98) 1.75 (0.90. 3.38)
Trajectory 3 14 13 1.56 (0.65. 3.73) 1.79 (0.68. 4.69)
Trajectory 4 10 13 1.98 (0.80. 4.89) 3.28 (1.14. 9.39)
Body mass index ≥ 25 kg/m2 (n= 322)*
Trajectory 1 93 75 1 (ref.) 1 (ref.)
Trajectory 2 54 49 1.16 (0.71. 1.91) 1.16 (0.65. 2.05)
Trajectory 3 16 18 1.36 (0.64. 2.86) 1.42 (0.62. 3.26)
Trajectory 4 7 10 1.80 (0.65. 5.00) 1.94 (0.60. 6.25)
OR odds ratio, CI confidence interval.
aAdjusted for age at the time of recruitment and hospital.
bAdditionally adjusted for BMI, menopausal status, an interaction term between BMI and menopausal status, calories, age at menarche, number of children,
age at first child, smoking status, educational level, chronic diseases, hormone replacement therapy use, previous benign breast lesions, family history of
breast cancer, physical activity, adherence to the Mediterranean dietary pattern.
cWomen with imputed BMI were excluded for this analysis (n= 68).
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might be more important in postmenopausal women, in whom
the ovary is not functioning, and even more important in those
with less amount of body fat, since fat is the main source of
oestrogens after menopause. However, differences across meno-
pausal status could likely be justified by age, since the older, the
more accumulated exposure. On the other hand, evidence
suggests that early onset of BC may be biologically and possibly
aetiologically distinct from BC arising in older women [55] as well
as, women diagnosed with BC at young ages may be more
affected by genetic susceptibility than by environmental factors
such as alcohol consumption [56]. Finally, higher circulating
oestrogen levels has also been proposed as the mechanism to
explain why obesity (which is associated with abnormally high
expression of the enzyme aromatase in the breast and increased
local oestrogen production) increases the risk of postmenopausal
BC [47, 57, 58].
When we examined the alcohol trajectories by pathological BC
subtype, a significant association was observed for the luminal
HER2 negative subtype (70% of the cases), while associations for
the other two subtypes failed to attain statistical significance.
However, the small sample size in some categories limits the
capacity of making firm conclusions. Previously, the European
Prospective Investigation into Cancer and Nutrition (EPIC) study
did not observe heterogeneity in associations of alcohol and BC
molecular subtype [34]. By contrast, alcohol consumption in
prospective analysis of the nurses’ health study was associated
with increased risk of luminal A and HER2-type BC, but not
significantly associated with other subtypes after 26 years of
follow-up. The authors suggested the notion of different etiologies
across subtypes [59].
Some limitations of the study must be recognised. One of major
limitations of this study is differential recall bias between cases
and controls. This is suggested by much higher ORs for alcohol
consumption in this study compared with that reported in the
prospective studies. However, the similarities between cases and
controls in terms of age, lifestyles, and environment, could reduce
this likelihood. Also, the reliability and validity of reports of alcohol
consumption in case–control studies are generally considered as
acceptable [60]. Concerns about selection and information bias
are legitimate as in any case–control study, but low rates of non-
participation are reassuring. The baseline characteristics were
similar between the women included in the study (n= 1578) and
those excluded for having missing data in relation to alcohol
consumption (n= 456), except for the educational level and
smoking. The higher educational level of the women included in
the study (compared with those excluded) may have affected the
representativeness of the sample. On the other hand, this higher
educational level allows for a better understanding of the
questionnaire and for a higher accuracy in their self-reported
information as well as may have even reduced potential
confounding by socioeconomic status and other potential factors.
Controls were selected by the case from non-blood relatives,
friends, neighbours, or work colleagues. This control identification
has the potential to make lifestyle, including alcohol consumption
patterns, more similar. Nonetheless, this approach is advanta-
geous in terms of reducing biases, including being more
homogeneous in their reproductive patterns, less potential
differences in understanding and reporting their exposures as
well as more homogeneity in their exposure to other environ-
mental risk factors associated with social class. This approach,
however, can lead to loss of efficiency due to overmatching and
loss of representativeness of the alcohol consumption. On the
other hand, this could serve to make the associations reported a
conservative estimate of the true magnitude.
The fact that nearly half of the women recruited had a very low
consumption of alcohol may have conditioned the statistical
power of our analyses, particularly when assessing BC risk by
tumour subtypes. Thus, the sample size in the fourth category
(heaviest drinkers) was quite limited and therefore stratification by
BMI and BC subtypes could have provided unstable estimates and
caution in the interpretation is necessary. Likewise, although in
this sample of Spanish women the total consumption of alcohol
comes mainly from beer and wine, sample size limited the
possibility of evaluating specific alcoholic beverages. Finally,
women (whose age ranges were 30–60 years) were asked for
alcohol consumption in the last 5 years, which applies to a
different age for each woman. However, we assumed that alcohol
habits likely remain similar throughout adulthood and conse-
quently this reported consumption was considered as the average
consumption during adulthood.
Using the GBTM, women were classified into different trajectory
groups (mutually exclusive), and in this way allows us to sift through
different patterns of alcohol consumption during life course. This
novel approach has the advantage over traditional analysis in that
this approach captures long term effects and critical or sensitive
periods throughout life [13, 14]. In that sense, these findings may
give a more reliable picture of how alcohol consumption across the
life span affects the risk of developing BC than those from studies
that measure cumulative exposure throughout life or only in a
specific life period. The study has a multicentric design with a high
participation rate (82%) and a large sample size, including
case–control pairs matched by region and age. Likewise, detailed
consumption of different alcoholic beverages was carefully col-
lected, as well as other relevant variables.
The topic is of a major public health relevance because of the
high prevalence of both exposure and outcome in our country.
While in the past women used to consume alcohol less often, and
in lower amounts as compared to men, currently, consumption is
almost equated between both sexes in many countries. Europe is
the heaviest drinking region in the world, for both men and
women, and 14 years of age is now the average age when boys
and girls start consuming alcohol [61]. In the most recent
European school survey project on alcohol [62], about 50% of
15–16-year old female students reported having drunk alcohol at
least once during the past month (the frequency of drinking
alcohol was 5.4 occasions per month on average), and 35% of
them also reported binge drinking, which was quite similar to their
male counterparts. These statistics are similar in Spain [63].
Consequently, from today´s habits of alcohol consumption among
teenagers, a future increase in the incidence of alcohol-related BC
can be expected and shifting the focus of BC prevention to this
age group is urgently needed.
CONCLUSION
The study’s findings indicate that the more alcohol is consumed
throughout life, the greater the risk of BC, especially in
postmenopausal women. Alcohol consumption during adoles-
cence could exert a great influence on BC risk. Likewise, alcohol
consumption trajectories displayed that those women who started
consuming alcohol in adolescence (≥5 g/day), continue to
consume similar amounts or more during adulthood. Therefore,
BC prevention strategies should target not only middle aged and
older women, but also include adolescent girls and young women,
whose current alcohol consumption is increasing alarmingly.
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